{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:38:56Z","timestamp":1788914336986,"version":"build-2803163510"},"reference-count":39,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with the primary myeloproliferative neoplasm polycythemia vera (PV) are at risk of the development of secondary malignancies, including skin cancers. This real-world, retrospective cohort study used Optum Market Clarity electronic health record data and linked medical and pharmacy claims from 70 million patients in the United States between 1 January 2007 and 31 December 2019 to assess the frequency of secondary malignancies in patients with a new or established diagnosis of PV (N = 82\u2009947 with \u22651 PV diagnosis; the final cohort for this study included 20\u2009089 patients) and the association of these cancers with patient characteristics and PV treatment. After indexing, 36% of patients had at least 1 non-PV malignancy (follow-up duration, 4.3 years). The most common nonhematologic malignancies were skin cancers, including melanoma and nonmelanoma skin cancer (NMSC). The incidence rate for a composite outcome of new-onset melanoma or NMSC was nearly twofold higher in patients who were exposed to hydroxyurea at any time than in those who were exposed to therapeutic phlebotomy alone. The strongest risk factors for occurrence of melanoma or NMSC in the observation period included older age, previous history of skin cancer, and preindex period use of cytoreductive medications. After controlling for potential confounders, a higher likelihood of developing new-onset melanoma or NMSC was observed in patients who received \u22654 weeks of hydroxyurea exposure vs those with no hydroxyurea exposure (hazard ratio, 1.33; 95% confidence interval, 1.17-1.50). This finding, which may have been influenced by different disease burdens among this diverse patient population, warrants further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019349","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:54:42Z","timestamp":1777488882000},"page":"4860-4871","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"first","affiliation":[{"name":"1Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[{"name":"2Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reaven","sequence":"additional","affiliation":[{"name":"3Strategic Health Resources, La Ca\u00f1ada, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-4501","authenticated-orcid":false,"given":"Susan","family":"Funk","sequence":"additional","affiliation":[{"name":"3Strategic Health Resources, La Ca\u00f1ada, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bellamy","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dinh","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oyuela","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Valone","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-9940","authenticated-orcid":false,"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[{"name":"5Protagonist Therapeutics, Inc, Newark, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"2026071409563730100_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","article-title":"Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review","volume":"5","author":"Parasuraman","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2026071409563730100_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-018-0529-x","article-title":"Polycythemia vera","volume":"19","author":"Spivak","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"2026071409563730100_bib3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2026071409563730100_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"issue":"7","key":"2026071409563730100_bib5","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/biomedicines11071925","article-title":"Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the polycythemia vera-advanced integrated models (PV-AIM) project","volume":"11","author":"Verstovsek","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"2026071409563730100_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2026071409563730100_bib7","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2026071409563730100_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann Hematol"},{"key":"2026071409563730100_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/VHRM.S429995","article-title":"Diagnosis and management of cardiovascular risk in patients with polycythemia vera","volume":"19","author":"Benevolo","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"2026071409563730100_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2010.08538.x","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa","volume":"153","author":"Fallah","year":"2011","journal-title":"Br J Haematol"},{"issue":"25","key":"2026071409563730100_bib11","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026071409563730100_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.12410","article-title":"Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis","volume":"94","author":"Pettersson","year":"2015","journal-title":"Eur J Haematol"},{"issue":"3","key":"2026071409563730100_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/ejh.12588","article-title":"Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"G\u00f3mez","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026071409563730100_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428194.2015.1071492","article-title":"Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study","volume":"57","author":"Khanal","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026071409563730100_bib15","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026071409563730100_bib16","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2024-200229","article-title":"Cancers in polycythemia vera and essential thrombocythemia: a before and after diagnosis survey and analysis of risk factors [abstract]","volume":"144","author":"Loscocco","year":"2024","journal-title":"Blood"},{"issue":"suppl_1","key":"2026071409563730100_bib17","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1182\/blood-2019-125387","article-title":"Impact of comorbidities and body mass index in patients with polycythemia vera: a PV-NET real world study","volume":"134","author":"Benevolo","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026071409563730100_bib18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026071409563730100_bib19","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026071409563730100_bib20","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"33","key":"2026071409563730100_bib21","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","article-title":"Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F","volume":"33","author":"Stein","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026071409563730100_bib22","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2026071409563730100_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3324\/haematol.2010.033779","article-title":"Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients","volume":"96","author":"Rumi","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2026071409563730100_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/10428194.2015.1041392","article-title":"Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera \u2013 single center experience","volume":"57","author":"Masarova","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026071409563730100_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ajh.25049","article-title":"Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review","volume":"93","author":"Marchetti","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2026071409563730100_bib26","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2026071409563730100_bib27","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026071409563730100_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026071409563730100_bib29","volume-title":"HYDROXYUREA capsules, for oral use [prescribing information]","year":"2024"},{"key":"2026071409563730100_bib30","volume-title":"JAKAFI\u00ae (ruxolitinib) tablets, for oral use [prescribing information]","year":"2023"},{"issue":"21","key":"2026071409563730100_bib31","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"2026071409563730100_bib32","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/S2152-2650(21)01820-6","article-title":"MPN-133: mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study","volume":"21","author":"Stein","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2026071409563730100_bib33","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2026071409563730100_bib34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"2026071409563730100_bib35","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2026071409563730100_bib36","unstructured":"Incyte Corporation\n          . FDA Approves Jakafi\u00ae (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera. 2014. Accessed 24 September 2024. https:\/\/investor.incyte.com\/news-releases\/news-release-details\/fdaapproves-jakafir-ruxolitinib-treatment-patients-uncontrolled."},{"key":"2026071409563730100_bib37","volume-title":"BESREMi (ropeginterferon alfa-2b-njft) injection, for subcutaneous use [prescribing information]","year":"2024"},{"key":"2026071409563730100_bib38","unstructured":"National Comprehensive Cancer Network\n          . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Myeloproliferative Neoplasms, Version 1.2025. Accessed 23 April 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"issue":"8","key":"2026071409563730100_bib39","first-page":"e16978","article-title":"Non-melanoma skin cancers in patients on hydroxyurea for Philadelphia chromosome-negative myeloproliferative neoplasms: a systematic review","volume":"13","author":"Gavini","year":"2021","journal-title":"Cureus"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4860\/2531567\/blooda_adv-2025-019349-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4860\/2531567\/blooda_adv-2025-019349-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:56:49Z","timestamp":1784037409000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4860\/568090\/Prevalence-incidence-and-risk-factors-of-secondary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019349","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,7,2]]}}}